Physician profile
Lorelee L Stock
NPI 1982667655
$1,545.29
in general payments reported to CMS, 2019-2025
15 companies · $905 in 2025
The $905 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $640 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $640.00 | 2020 | |
| Amgen INC. | $268.38 | 2025 | Krystexxa, Evenity, Repatha |
| Corcept Therapeutics | $200.88 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $85.45 | 2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $63.38 | 2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $58.68 | 2025 | Acthar |
| Astellas Pharma US INC | $50.91 | 2025 | Veozah |
| Ucb, INC. | $39.75 | 2025 | Bimzelx |
| Alkermes, INC. | $25.29 | 2025 | Vivitrol |
| Heartflow, INC. | $23.35 | 2025 | |
| Recordati_rare_diseases_inc. | $23.07 | 2025 | Isturisa |
| Chiesi USA, INC. | $19.08 | 2025 | Juxtapid |
| Astrazeneca Pharmaceuticals LP | $18.79 | 2025 | Breztri |
| Novo Nordisk INC | $14.59 | 2025 | |
| Lilly USA, LLC | $13.69 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorelee Stock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.